source
- Novartis drops mid-stage radioligand therapy 177Lu-NeoB after weak early dataNovartis has discontinued its mid-stage radioligand therapy 177Lu-NeoB, which was being tested for breast cancer and other solid tumors. The company said early clinical data did not show enough ef…
- Dyne Therapeutics receives early 2027 FDA decision date for Duchenne therapy, analysts anticipate smooth reviewDyne Therapeutics' investigational Duchenne muscular dystrophy therapy, zeleciment rostudirsen, has had its BLA accepted by the FDA with a target action date of Jan 21, 2027. Analysts at Oppenheim…